Edwards Lifesciences Corporation $EW Shares Sold by Citigroup Inc.

Citigroup Inc. decreased its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 37.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 872,067 shares of the medical research company’s stock after selling 513,348 shares during the quarter. Citigroup Inc. owned approximately 0.15% of Edwards Lifesciences worth $67,821,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Brighton Jones LLC purchased a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $266,000. Strategic Blueprint LLC boosted its holdings in shares of Edwards Lifesciences by 66.0% in the 2nd quarter. Strategic Blueprint LLC now owns 6,028 shares of the medical research company’s stock valued at $471,000 after purchasing an additional 2,397 shares during the last quarter. Sage Mountain Advisors LLC grew its stake in shares of Edwards Lifesciences by 26.5% during the 2nd quarter. Sage Mountain Advisors LLC now owns 3,689 shares of the medical research company’s stock valued at $289,000 after buying an additional 773 shares during the period. Focus Partners Advisor Solutions LLC increased its holdings in shares of Edwards Lifesciences by 20.3% during the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 8,888 shares of the medical research company’s stock worth $695,000 after buying an additional 1,499 shares during the last quarter. Finally, Linden Thomas Advisory Services LLC increased its holdings in shares of Edwards Lifesciences by 1.7% during the 2nd quarter. Linden Thomas Advisory Services LLC now owns 11,400 shares of the medical research company’s stock worth $892,000 after buying an additional 186 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Raymond James Financial upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 target price on the stock in a report on Monday, November 3rd. Piper Sandler restated an “overweight” rating and issued a $100.00 price objective (up from $98.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Canaccord Genuity Group set a $87.00 price objective on Edwards Lifesciences and gave the company a “hold” rating in a research note on Wednesday, December 17th. Stifel Nicolaus set a $110.00 target price on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research report on Tuesday, January 20th. Finally, UBS Group restated a “neutral” rating and issued a $94.00 price target on shares of Edwards Lifesciences in a report on Wednesday, February 4th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $96.14.

Insiders Place Their Bets

In related news, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction on Friday, January 9th. The shares were sold at an average price of $85.70, for a total value of $87,328.30. Following the completion of the sale, the vice president owned 22,002 shares in the company, valued at approximately $1,885,571.40. The trade was a 4.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 11,340 shares of the company’s stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $85.66, for a total transaction of $971,384.40. Following the completion of the sale, the vice president directly owned 31,870 shares in the company, valued at $2,729,984.20. This represents a 26.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 43,804 shares of company stock worth $3,699,082 in the last three months. 0.34% of the stock is owned by insiders.

Edwards Lifesciences Price Performance

EW opened at $82.54 on Tuesday. The company has a fifty day simple moving average of $82.79 and a 200 day simple moving average of $81.08. The firm has a market cap of $47.90 billion, a price-to-earnings ratio of 45.11, a PEG ratio of 2.08 and a beta of 0.94. Edwards Lifesciences Corporation has a twelve month low of $65.94 and a twelve month high of $87.89. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The firm had revenue of $1.57 billion during the quarter, compared to analysts’ expectations of $1.54 billion. During the same period in the previous year, the company earned $0.59 earnings per share. The business’s quarterly revenue was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Equities research analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.